Literature DB >> 8058360

Characterization of the effector mechanisms of a transmission-blocking antibody upon differentiation of Plasmodium berghei gametocytes into ookinetes in vitro.

G R Ranawaka1, A R Alejo-Blanco, R E Sinden.   

Abstract

The transmission-blocking monoclonal antibody 13.1, which recognizes the ookinete surface antigen Pbs21 of Plasmodium berghei, and an IgG2a isotype control antibody 26.37 were purified by caprylic acid and ammonium sulphate precipitation. Fab fragments were prepared by papain digestion. IgG but not Fab from antibody 13.1 reduced ookinete formation by P. berghei in culture by as much as 94% at a concentration of 100 micrograms/ml. There was little difference in antibody efficacy in the range 6.25-400 micrograms/ml in this assay. The parasite was most sensitive to antibody activity in the first 6-9 h of culture, i.e. the gamete/zygote and early retort stages. Peripheral blood leucocytes (PBL) were essential to achieve maximal inhibition by mAb 13.1 (activity was abrogated totally if PBL were removed). Together the data suggest that one of the mechanisms of action of this antibody is antibody-mediated PBL killing. Phagocytosis of parasites was noted in these experiments in all cultures. We have not attempted in this study to distinguish between Fc-mediated opsonization, as opposed to antibody-dependent cellular cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058360     DOI: 10.1017/s0031182000077702

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  9 in total

1.  P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions.

Authors:  A M Tomas; G Margos; G Dimopoulos; L H van Lin; T F de Koning-Ward; R Sinha; P Lupetti; A L Beetsma; M C Rodriguez; M Karras; A Hager; J Mendoza; G A Butcher; F Kafatos; C J Janse; A P Waters; R E Sinden
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Host cell preference and variable transmission strategies in malaria parasites.

Authors:  Sarah E Reece; Alison B Duncan; Stuart A West; Andrew F Read
Journal:  Proc Biol Sci       Date:  2005-03-07       Impact factor: 5.349

Review 3.  Determinants of Malaria Transmission at the Population Level.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

4.  Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230.

Authors:  J Healer; D McGuinness; P Hopcroft; S Haley; R Carter; E Riley
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

5.  Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity.

Authors:  T Tsuboi; Y M Cao; Y Hitsumoto; T Yanagi; H Kanbara; M Torii
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 6.  Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings.

Authors:  Charles Mulamba; Chris Williams; Katharina Kreppel; Jean Bosco Ouedraogo; Ally I Olotu
Journal:  Malar J       Date:  2022-06-02       Impact factor: 3.469

Review 7.  Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?

Authors:  Luke A Baton; Lisa C Ranford-Cartwright
Journal:  Malar J       Date:  2005-02-25       Impact factor: 2.979

Review 8.  Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.

Authors:  Roos M de Jong; Surafel K Tebeje; Lisette Meerstein-Kessel; Fitsum G Tadesse; Matthijs M Jore; Will Stone; Teun Bousema
Journal:  Immunol Rev       Date:  2019-12-16       Impact factor: 12.988

9.  Hemolytic C-type lectin CEL-III from sea cucumber expressed in transgenic mosquitoes impairs malaria parasite development.

Authors:  Shigeto Yoshida; Yohei Shimada; Daisuke Kondoh; Yoshiaki Kouzuma; Anil K Ghosh; Marcelo Jacobs-Lorena; Robert E Sinden
Journal:  PLoS Pathog       Date:  2007-12       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.